Form 4: Boundless Bio's Chief Medical Officer, Klaus Wagner, Acquires Stock Options
SEC Filing
Klaus Wagner, Chief Medical Officer of Boundless Bio, acquired stock options on March 27, 2024, according to a Form 4 filing with the SEC.
Summary
- Klaus W. Wagner, the Chief Medical Officer of Boundless Bio, Inc. (BOLD), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on March 27, 2024, where Wagner acquired stock options.
- Wagner acquired 41,745 stock options with an exercise price of $16.
- The options vest in 48 substantially equal monthly installments beginning on April 27, 2024, and expire on March 26, 2034.
- Following the reported transaction, Wagner directly owns 41,745 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Form 4) regarding stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of stock option transaction |
| 04/27/2024 | First vesting date of the stock options |
| 03/26/2034 | Expiration date of the stock options |
| 03/29/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.